Chicago-based, investment management firm Harrison Street has entered a ground lease with MIT for the three-building, 677K SF Osborn Triangle life science complex near Kendall Square. The deal surpassed $1B, or just over $1,600/SF, setting a neighborhood portfolio price record, according to sources familiar with the deal. “Osborn Triangle is a one-of-a-kind complex serving as […]

Vertex Pharmaceuticals and Kymera Therapeutics have announced that the two companies have entered into a four-year strategic research and development collaboration to advance small molecule protein degraders against multiple targets.  The collaboration will leverage Kymera’s expertise in targeted protein degradation and its proprietary PegasusTM drug discovery platform and Vertex’s scientific, clinical, and regulatory capabilities to […]

Gilead Sciences and Goldfinch Bio have announced a strategic collaboration to discover, develop and commercialize a pipeline of innovative therapeutics for diabetic kidney disease (DKD) and certain orphan kidney diseases. Under the multi-year collaboration, Gilead has exclusive options to license worldwide rights to certain products directed toward targets emerging from Goldfinch’s proprietary Kidney Genome Atlas™ (KGA), […]

ElevateBio has established ElevateBio BaseCamp, a single R&D, process development and cGMP manufacturing company, to address the process development and manufacturing barriers that can impede the successful development of cell and gene therapies. BaseCamp is providing these and other services across ElevateBio’s portfolio companies and selected strategic partners, enabling them to access state of the […]

Servier Pharmaceuticals, a U.S. subsidiary of the global French pharmaceutical company Servier Group, has officially opened its American headquarters in Boston’s new Innovation District. The facility already employs 100 professionals in marketing, business development, R&D and strategic support functions. That figure is projected to double within five years. Servier Group also established the first office […]

Alnylam and Regeneron have announced a collaboration to discover, develop and commercialize new RNA interference (RNAi) therapeutics with a focus on disease targets expressed in the eye and central nervous system (CNS), in addition to a select number of targets expressed in the liver. The collaboration will leverage both companies’ scientific and technological expertise and […]

Thermo Fisher Scientific has announced it will acquire Brammer Bio for approximately $1.7 billion in cash. Brammer Bio is a leading viral vector contract development and manufacturing organization (CDMO) with nearly 600 employees at primary locations in Massachusetts and Florida. Brammer Bio is on track to deliver $250 million of revenue in 2019 and expects to […]